Suchergebnisse

The first Junior Scientist Zoonoses Meeting (JSZM) took place in 2013. Over the following years, it developed into an established annual event for young researchers in the zoonoses research community. It is a forum for young scientists to exchange information, train their own expertise and build their own network. The designed venue for the meeting in 2020 was the Fraunhofer-Institute for Cell Therapy and Immunology in Leipzig. Everything was prepared and ready. The program was finalised, the guest speakers invited, the poster walls ordered and the catering menu set. But then, SARS-CoV-2

Two tools are of crucial importance for the efficient fight against a pathogen: a vaccine to prevent people or animals from becoming infected in the first place and drugs to provide adequate treatment for those who are ill. Both of these are still lacking in the fight against COVID-19, but great research efforts are being made to change this as quickly as possible. Vaccine development usually takes several years and has a relatively high failure rate [1]. This is partly due to the fact that in the development of vaccines that are ultimately administered to healthy people, the risk-benefit

In Germany, as in the rest of the world, research into suitable drugs for the treatment of COVID-19 patients is in full swing. A drug that has been shown to be effective in preclinical studies and will soon be tested on patients is produced by a research company in Tübingen, Atriva Therapeutics GmbH . Founded in 2015, the company specialises in the development of antiviral therapies for severe respiratory diseases such as influenza or COVID-19. Chairman of the company's advisory board is the head of the office site of the German Research Platform for Zoonoses in Münster, Prof. Dr. Stephan

We are pleased to announce that the registration and the abstract submission for the " Zoonoses 2020 - International Symposium on Zoonoses Research " is now open. You`ll find more information about the " Zoonoses 2020 - International Symposium on Zoonoses Research " here

Researchers in Germany are required to follow the rules of "good scientific practice" in their work. These rules are an important quality assurance tool, which also aim to ensure smooth cooperation between scientists and define common rules of conduct. In Germany, the " Ombudsman for Science " committee set up by the DFG acts as a central advisory body for all scientists and academics conducting research in Germany on questions and conflicts related to good scientific practice. Dr. Czesnick is the head of the committee's office. We asked her some questions about the work of the committee and

Science communication is an important part of research. Without it, the transfer of new findings from research into practice would not be possible. Especially in the face of the coronavirus pandemic, it is clear how important "good" science communication is and that it can be much more complex than many initially assume. "It is not just a matter of explaining what a virus is. It is much more than that," says Prof. Dr. Leßmöllmann . She is professor of science communication with a focus on linguistics at the Karlsruhe Institute of Technology (KIT). Prior to that, she was Professor of Journalism

The coronavirus pandemic affects all parts of society regardless of factors such as age, gender or social status. Much is still uncertain about SARS-CoV-2, the disease COVID-19 and the impact of the pandemic on the economy and society. As a result, the attention currently devoted to research is immense. Hopes are high that soon results will be available that are applicable in practice immediately. Science is trying to meet the demand and is working at an enormous speed. Consequently, the world is flooded daily with a multitude of new scientific publications. The questions that arise are to